PARD Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Poniard Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | -99.00% |
| 5 Year Change | -99.75% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PARD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.0% |
| 1Y | 0% | 18.0% | 32.4% |
Return vs Industry: PARD underperformed the US Biotechs industry which returned 19.3% over the past year.
Return vs Market: PARD underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| PARD volatility | |
|---|---|
| PARD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PARD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PARD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | n/a | n/a |
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors.
Poniard Pharmaceuticals, Inc. Fundamentals Summary
| PARD fundamental statistics | |
|---|---|
| Market cap | US$149.00 |
| Earnings (TTM) | -US$16.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PARD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PARD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.23m |
| Earnings | -US$16.23m |
Last Reported Earnings
Sep 30, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PARD perform over the long term?
See historical performance and comparison